Use of daptomycin in the treatment of prosthetic joint infections: A prospective observational study of 30 patients with infected prosthetic joint infections

Internet Journal of Infectious Diseases

Volumn 7, Issue 1, 2009, Pages

  Antony, Suresh J ^a   Tiscareno Grajeda, Iliana ^a   Misenhiemer, Gregory ^b   Heyderman, Jacob ^b  

^a Center for Infectious Diseases and Travel Medicine   (United States)

^b NONE

Author keywords

Daptomycin; Methicillin resistant Staphylococcus aureus; Prosthetic joint infections

Indexed keywords

DAPTOMYCIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INFECTIOUS ARTHRITIS; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; PROSTHESIS INFECTION; TREATMENT DURATION; TREATMENT FAILURE;

EID: 77953377181     PISSN: None     EISSN: 15288366     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Barry AL, Fuchs PC, Brown SD. In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob Agents Chemother 2001;45:1919-22. (s)
2. Fluit AC, Schmitz FJ, Verhoef J, et al. In vitro activity of daptomycin against Gram-positive European clinical isolates with defined resistance determinants. Antimicrob Agents Chemother 2004;48:1007-11. (s)
3. Snydman DR, Jacobus NV, McDermott LA, et al. Comparative in vitro activities of daptomycin and vancomycin against resistant Gram-positive pathogens. Antimicrob Agents Chemother 2000;44:3447-50. (s)
4. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant Gram-positive pathogens. Clin Infect Dis 2004;38:994-1000. (s)
5. Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 2003;47:2538-44. (s)
6. Peterson PJ, Bradford PA, Weiss WJ, et al. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens. Antimicrob Agents Chemother 2002;46:2595-601. (s)
7. Cha R, Grucz RG. Daptomycin dose-effect relationship against resistant gram-positive organisms. Antimicrob Agents Chemother 2003;47:1598-603. (s)
8. Dandekar PK, Tessier PR, Williams P, et al. Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. J Antimicrob Chemother 2003;52:405-11. (s)
9. Johnson AP, Mushtaq S, Warner M, et al. Activity of daptomycin against multi-resistant gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid. Int J Antimicrob Agents 2004;24:315-19. (s)
10. Lee DC, Barlas D, Ryan JG, et al. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: prevalence and predictors of colonization in patients presenting to the emergency department from nursing homes. J Am Geriatr Soc 2002;50:1463-5. (s)
11. Sader HS, Fritsche TR, Jones RN. Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin. Antimicrob Agents Chemother 2006;50:2330-6. (s)
12. Mangili A, Bica I, Snydman DR, et al. Daptomycin-resistant, methicillinresistant Staphylococcus aureus bacteremia. Clin Infect Dis 2005;40:1058-60. (s)
13. Skiest DJ. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 2006;44:655-6. (s)
14. Marty FM, Yeh WW, Wennersten CB, et al. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol 2006;44:595-7. (s)
15. Patel JB, Jevitt LA, Hageman J, et al. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin Infect Dis 2006;42:1652-3. (s)
16. Sakoulas G, Alder J, Thauvin-Eliopoulos C, et al. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 2006;50:1581-5. (s)
17. Cui L, Tominaga E, Neoh HM, et al. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycinintermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006;50:1079-82. (s)
18. Cubicin (daptomycin for injection) prescribing information. Lexington, MA: Cubist Pharmaceuticals, September 2003. Report No.:1108090803. (s)
19. Barberan J. Management of infections of osteoarticular prosthesis. Clin Microbiol Infect 2006;12(suppl 3):93-101. (s)
20. Widmer AF. New developments in diagnosis and treatment of infection in orthopedic implants. Clin Infect Dis 2001;33(suppl 2):S94-106. (s)
21. Berbari EF, Hanssen AD, Duffy MC, et al. Risk factors for prosthetic joint infection: case-control study. Clin Infect Dis 1998;27:1247-54. (s)
22. Sperling JW, Kozak TK, Hanssen AD, et al. Infection after shoulder arthroplasty. Clin Orthop Relat Res 2001;382:206-16. (s)
23. Laffer R, Ruef C. Diagnosis and treatment of prosthetic joint infections. Z Rheumatol 2006;65:12,14-7. (s)
24. Trampuz A, Zimmerli W. Prosthetic joint infections: update in diagnosis and treatment. Swiss Med Wkly 2005;135:243-51. (s)
25. Williams RJ, Henderson B, Sharp LJ, et al. Identification of a fibronectin-binding protein from Staphylococcus epidermidis. Infect Immun 2002;70:6805-10. (s)
26. Lentino JR. Infections associated with prosthetic knee and prosthetic hip. Curr Infect Dis Rep. 2004;6:388-92. (s)
27. Zimmerli W, Waldvogel FA, Vaudaux P, et al. Pathogenesis of foreign body infection: description and characteristics of an animal model. J Infect Dis 1982;146:487-97. (s)
28. Diekema DJ, Pfaller MA, Schmitz FJ, et al.. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001;32 (suppl. 2):S114-32. (s)
29. von Eiff C, Peters G, Heilmann C. Pathogenesis of infections due to coagulase-negative staphylococci. Lancet Infect Dis 2002;2:677-85. (s)
30. Bernard L, Hoffmeyer P, Assal M, et al. Trends in the treatment of orthopedic prosthetic infections. J Antimicrob Chemother 2004;53:127-9. (s)
31. Lodise TP Jr, McKinnon PS. Burden of methicillin-resistant Staphylococcus aureus: focus on clinical and economic outcomes. Pharmacotherapy 2007;27:1001-12. (s)
32. Appelbaum PC. Reduced glycopeptide susceptibility in methicillinresistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 2007;30:398-408. (s)
33. Deresinski S. Vancomycin: does it still have a role as an antistaphylococcal agent? Expert Rev Anti Infect Ther 2007;5:393-401. (s)
34. Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structured infections. Clin Infect Dis 2004;38:1673-81. (s)
35. Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother 2005;55:240-5. (s)
36. Naber KG, Eisenstein BI, Tally FP. Daptomycin versus ciprofloxacin in treatment of complicated urinary tract infection due to Gram-positive bacteria. Infect Dis Clin Pract 2004;12:322-7. (s)
37. Mader JT, Adams K. Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment for experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits. Antimicrob Agents Chemother 1989;33:689-92. (s)
38. Vandaux P, Francois P, Bisognano C, et al. Comparative efficacy of daptomycin and vancomycin in the therapy of experimental foreign body infection due to Staphylococcus aureus. J Antimicrob Chemother 2003:52:89-95. (s)
39. Giulieri SG, Graber P, Ochsner PE, et al. Management of infection associated with total hip arthroplasty according to a treatment algorithm. Infection 2004;32:222-8. (s)
40. Widmer AF, Gaechter A, Ochsner PE, et al. Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. Clin Infect Dis 1992;14:1251-3. (s)
41. Zimmerli W, Widmer AF, Blatter M, et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized control trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998;279:1537-41. (s)
42. Rao N, Hamilton CW. Efficacy and safety of linezolid for Gram-positive orthopedic infections: a prospective case series. Diagn Microbiol Infect Dis 2007;59:173-9. (s)
43. Bassetti M, Vitale F, Melica G, et al. Linezolid in the treatment of Grampositive prosthetic joint infections. J Antimicrob Chemother 2005;55:387-90. (s)
44. Salgado CD, Dash S, Cantey JR, et al. Higher risk of failure of methicillin-resistant Staphylococcus aureus prosthetic joint infections. Clin Orthop Relat Res 2007;461:48-53. (s)
45. Rouse MS, Steckelberg JM, Patel R, et al. In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin- resistant staphylococci associated with endocarditis and bone and joint infection. Diagn Microbiol Infect Dis 2007;58:363-5. (s)
46. Ries MD. Vancomycin-resistant Enterococcus infected total knee arthroplasty. J Arthroplasty 2001;16:802-5. (s)